CJC-1295

Growth hormone–releasing hormone (GHRH) analog

This page is educational only and is not medical advice. It is not an endorsement to use this compound. See the Educational Disclaimer for details.

Quick Answer

A synthetic peptide designed to mimic and extend the activity of growth hormone–releasing hormone, which stimulates the pituitary gland to release growth hormone. Exists in variants with and without a "drug affinity complex" (DAC) that extends its half-life — these variants should be distinguished when discussed, not treated as one compound.

Why People Are Interested

Popular in the growth-hormone-optimization conversation as a longer-acting alternative to older GHRH-pathway compounds, often discussed alongside ipamorelin as a "stack."

What People Hope It May Do

Increased growth hormone release for body-composition and recovery goals — a plausible mechanism, but one studied mostly in small or early-stage settings rather than large controlled trials. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)

Potential / Research Areas

Growth hormone secretion dynamics

Potential body-composition-related research questions (mostly community-driven interest rather than a deep clinical trial base)

How It May Work

Binds GHRH receptors in the pituitary to stimulate growth hormone release, similar to natural GHRH but with a longer duration of action than the native hormone.

What Human Research Shows

Limited public clinical trial data; most available human information comes from earlier-stage or smaller studies rather than large controlled trials of the kind supporting an FDA-approved product.

What Preclinical Research Shows

Growth-hormone-axis pharmacology research, with more extensive preclinical characterization than human data.

Element Evidence Snapshot™

Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.

Human ResearchLimited
Preclinical ResearchModerate
Clinical Trial ActivityNone Identified
Real-World InterestModerate
Regulatory StatusNot Approved
Research MomentumLimited

"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.

What People Report

Real-World / Anecdotal Experience — in development. Element Health Labs hasn't yet compiled a reliable synthesis of public anecdotal reports for CJC-1295. When this section is live, it will summarize commonly reported themes from public discussion, clearly separated from the scientific evidence above. Anecdotal reports are not clinical evidence, and individual experiences vary. See Real Experiences for how this is being built.

What Experts Are Saying

Curated commentary specific to CJC-1295 is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.

Clinical Trials

For the current, authoritative list of registered trials involving CJC-1295, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.

Potential Risks & Side Effects

No comprehensive, controlled human safety database exists publicly at the scale of an approved drug. Effects related to growth hormone elevation generally are an active research and clinical-monitoring topic that requires licensed medical oversight, not consumer self-guidance.

Regulatory Status

Not FDA-approved. Not available as an approved prescription product for any indication; commonly found in the gray-market "research chemical" space, which this business does not sell into.

What We Still Don't Know

Long-term safety of sustained growth-hormone-axis stimulation outside a supervised clinical context, and whether real-world body-composition outcomes match the mechanism's promise.

Limitations of Evidence

Sparse controlled human data; variant (with/without DAC) is often not clearly distinguished in available sources, which is itself a data-quality problem worth flagging in any article.

Key Takeaway. CJC-1295 is a real area of scientific and public interest — but interest, mechanism plausibility, and proof are three different things. As of this review: human research is limited, preclinical research is moderate, and its regulatory status is Not Approved. Read the sections above — not just this summary — before forming a view, and talk to a licensed healthcare provider before making any health decision.

Keep Researching

Key Studies

Verified directly against the PubMed abstract via NCBI eutils (PMID 16352683) on 2026-10-11. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA, Journal of Clinical Endocrinology & Metabolism, 2006: two randomized, placebo-controlled, double-blind, ascending-dose trials (28 and 49 days) in healthy adults aged 21–61. A single injection produced dose-dependent increases in plasma GH of 2- to 10-fold for 6+ days and IGF-I of 1.5- to 3-fold for 9–11 days; estimated half-life 5.8–8.1 days, with IGF-I remaining elevated up to 28 days after repeated dosing. No serious adverse events reported. This trial used the long-acting DAC-bearing form of CJC-1295 (consistent with the multi-day half-life reported) — it specifically supports the DAC variant, not an undifferentiated claim about "CJC-1295" generally. No separate human pharmacokinetic verification was found for the non-DAC variant; that distinction should stay explicitly hedged rather than implied as covered by this trial.

References

  • Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PMID: 16352683. Verified via NCBI eutils abstract fetch, 2026-10-11.

Last reviewed: 2026-10-11 (Key studies/References added and independently verified — see note above)

Sources. The key studies and references above are our current research notes, including dating/sourcing details where we have them — read each one for its own level of verification rather than treating this list as a uniform claim. This page will not publish claims backed by unverified or fabricated citations.
Last reviewed: 2026-10-11 (Key studies/References added and independently verified — see note above)